Table 2

The National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) composite and subscale score in patients with Behçet disease before and after receiving infliximab (IFX) treatment

NEI VFQ-25 scale	No	Mean (SD) score before IFX	Mean (SD) score IFX 6M	p Value versus before IFX	Mean (SD) score IFX 12M	p Value versus before IFX
General health	20	31.3 (13.8)	73.8 (9.9)	0.0001*	77.5 (11.2)	<0.0001*
General vision	20	48.0 (10.1)	78.0 (8.9)	0.0001*	82.0 (11.1)	0.0001*
Ocular pain	20	78.8 (12.9)	98.1 (4.6)	0.0002*	98.1 (4.6)	0.0002*
Near activities	20	53.3 (4.9)	85.0 (14.1)	0.0001*	87.4 (11.9)	0.0001*
Distance activities	20	60.6 (6.8)	81.2 (12.6)	0.0001*	85.2 (10.8)	0.0001*
Social functioning	20	69.6 (10.2)	90.0 (12.6)	0.0001*	90.0 (12.6)	0.0001*
Mental health	20	43.4 (15.3)	91.9 (14.2)	0.0001*	92.6 (13.7)	0.0001*
Role difficulties	20	53.2 (14.0)	92.0 (10.9)	0.0001*	92.6 (10.2)	0.0001*
Dependency	20	77.3 (12.7)	94.6 (10.2)	0.0001*	95.4 (9.9)	0.0001*
Driving	15	58.3 (12.2)	75.0 (18.9)	0.0362*	85.0 (18.5)	0.0059*
Colour vision	20	82.5 (11.8)	87.5 (12.8)	0.2059	92.5 (11.8)	0.0209*
Peripheral vision	20	75.0 (16.2)	93.8 (11.1)	0.0004*	93.8 (11.1)	0.0004*
Composite score	20	63.6 (8.9)	88.0 (9.1)	0.0001*	90.3 (8.7)	0.0001*

*Statistically significant value; p<0.05 (Wilcoxon signed rank test).
IFX6M, IFX12M, 6 and 12 months after receiving infliximab;